Dr. Matthew Davids

Dr. Matthew Davids

Associate Director, Center for CLL
Dana-Farber Cancer Institute

Dr. Matthew Davids is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, an Assistant Professor of Medicine at Harvard Medical School and the Associate Director of the Dana-Farber CLL Center.

Dr. Davids has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies.

Diagnosis

The IGHV Mutation is Key to CLL Prognosis
Treatment

An Oral Medicine for People With Relapsed CLL: Idelalisib
Treatment

What is CAR-T Therapy?
Treatment

Initial Treatment Options for CLL Depend on Age
Treatment

What are the Stages of CLL?
Later Stage

Do I Need A Stem Cell Transplant For CLL?
Later Stage

CLL is Not Considered Curable So Treatment May Resume Years Later
Later Stage

Physical Symptoms Are Usually Seen in Advanced Stages of CLL
Diagnosis

Tests That Can Inform the Prognosis of CLL
Treatment

Clinical Trials Test State-of-the-Art Cancer Treatments